Medically reviewed

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Norheum

Property	Description
Active ingredient	Betamethasone Dipropionate
Form	Cream, Ointment, Lotion, or Gel
Pharmacological class	Corticosteroid (Synthetic Glucocorticoid)
Common use	Relief of inflammatory and pruritic skin manifestations
Origin	Synthetic

What is Norheum and Its Pharmacological Class?

Norheum is a prescription-only medicinal product defined by its active ingredient, Betamethasone Dipropionate, and is classified as a potent synthetic glucocorticoid. The compound belongs to the corticosteroid class, which includes steroid hormones and their synthetic analogs used primarily for their anti-inflammatory and immunosuppressive properties. The use of the Dipropionate ester form is a key feature, as it is clinically recognized for providing greater stability and enhanced skin penetration compared to less potent Betamethasone derivatives.

Composition and Topical Dosage Forms

Norheum is a single active ingredient product, containing only Betamethasone Dipropionate as the therapeutic agent for dermal use. It is formulated for topical application and is typically supplied in multiple dosage form(s), including a cream, ointment, lotion, or gel. The active ingredient is suspended in an inert base/vehicle—such as a hydrophilic emollient cream base—which is necessary for product stability and to facilitate the effective delivery of the medication to the skin.

The General Purpose of This Potent Agent

The general purpose of Norheum is to provide powerful, localized suppression of severe skin inflammation and associated symptoms. The drug’s core function is to exert a rapid anti-inflammatory action and a strong antipruritic action by reducing swelling, redness, and itching. As a high-potency agent, Betamethasone Dipropionate is fundamentally designed for the management of pronounced inflammatory manifestations and associated pruritic manifestations characteristic of corticosteroid-responsive dermatoses.

Regulatory References

Betamethasone Dipropionate - DailyMed (NIH)

What side effects are possible with Norheum?

Possible Side Effects and Safety Information for Norheum

Official regulatory documents classify adverse reactions to Norheum based on System Organ Class and standardized frequency categories, such as Very common (ge 1/10), Common (ge 1/100 to <1/10), and Rare (ge 1/10,000 to <1/1,000).

Key Adverse Reactions and Safety Concerns

Classification	Detail	Regulatory Mandate
Serious Adverse Reactions (SAE)	Events requiring hospitalization, causing persistent disability, or being life-threatening or fatal.	Mandatory expedited reporting to regulatory authorities (e.g., FDA, EMA).
Liver Toxicity	Symptomatic elevations of liver enzymes (ALT, AST) or bilirubin of more than 3 times the upper limit of normal (ULN), or asymptomatic elevations of more than 5 times ULN.	Requires discontinuation of the medication.
System Organ Classes	Reactions are cataloged by the system they affect, including Blood and lymphatic system disorders, Nervous system disorders, Infections and infestations, and Hepatobiliary disorders.	Used for structured data analysis and safety monitoring.

Safety Restrictions and Monitoring

The safety profile is continually monitored based on clinical trial data and post-marketing surveillance, informed by exposure-response information to identify and avoid dose-related toxicity. For certain populations, such as pregnant or breastfeeding women, specific safety considerations exist within the regulatory framework for product use. Regulatory guidance mandates a structured approach to assessing the drug's safety, requiring the reporting of both common and serious adverse events to ensure the benefit-risk assessment remains valid throughout the product lifecycle.

Overdose and Emergency Response

Overdose and When to Seek Help

Norheum overdose presents a critical risk of severe liver damage, potentially progressing to fatal acute hepatic failure. This risk profile is consistent with regulatory warnings for drugs that can cause dose-dependent hepatotoxicity. Immediate medical intervention is mandated due to the severity and time-critical nature of the toxicity.

Clinical Manifestations and Risk

The most severe consequence of overdose is the potential for liver failure. However, initial symptoms can be non-specific, often including nausea, vomiting, and abdominal pain, or may be absent altogether. Crucially, the clinical and laboratory evidence of serious liver injury may be delayed by 24 to 72 hours after the exposure, even in cases of severe overdose. Overdose may occur from a single large ingestion or from chronic ingestion of supratherapeutic amounts.

Pre-existing conditions, particularly chronic alcohol use or underlying liver disease, increase an individual’s susceptibility to the toxic effects and may lower the threshold for severe injury.

Required Emergency Action

Immediate emergency medical help must be sought for any suspected or confirmed overdose, regardless of whether symptoms are present. Do not wait for symptoms to appear or worsen. Rapid medical treatment, which typically involves administering a specific antidote, is most effective when initiated promptly, ideally within 8 hours of ingestion, to prevent progressive, severe liver damage. Any delay significantly compromises the outcome.

Therapeutic Uses of Norheum

What Norheum Treats: Main Uses and Benefits

Norheum is used for the relief of inflammatory and pruritic manifestations and is applied across conditions marked by increased physiological stress. It is commonly used across corticosteroid-responsive dermatoses, including severe plaque psoriasis and acute exacerbations of atopic dermatitis (eczema). It is relevant in clinical settings marked by pronounced inflammatory manifestations that require additional symptomatic support.

The medication is applied to manage acute symptom clusters that interfere with daily functioning, such as debilitating itching (pruritus), noticeable redness, and swelling. This symptomatic relief helps patients cope more steadily with difficult episodes, which may contribute to improved day-to-day comfort and stability during symptomatic periods. Norheum is also considered relevant for conditions presenting with moderate-to-severe symptoms or lesions where symptoms may intensify temporarily.

“It is commonly used to ease the intensity of debilitating itching and manage visible inflammation during flare-ups.”

Quick Fact: Relief for Pruritus and Inflammation

Norheum is relevant for easing symptoms that cluster into patterns requiring supportive management in the skin: symptoms related to inflammatory or irritative states (redness, swelling, heat) and symptoms that create noticeable physiological strain (intense itching). The benefit is supportive relief that helps ease the overall symptom burden.

Regulatory References

FDA Drug Label via DailyMed/NIH

Eligibility and Restrictions for Use

Who Can and Cannot Use Norheum?

Norheum is a prescription medicine governed by strict population eligibility rules outlined in official regulatory documents. Use is established and indicated for patients 13 years of age and older.

Absolute Contraindications

Norheum must not be used if you have a documented hypersensitivity to the active ingredient, other corticosteroids, or any component of the formulation. It is also contraindicated for specific skin conditions, including rosacea, acne vulgaris, perioral dermatitis, or in the presence of untreated bacterial, fungal, or viral infections (such as herpes simplex or chickenpox) at the treatment site. Use in infants under one year of age is also strictly contraindicated.

Restricted Populations

Use in patients 12 years of age and younger is not recommended as safety and effectiveness have not been established in this age group. Caution is required for patients with pre-existing conditions that increase systemic absorption risk, such as liver impairment, or those with conditions sensitive to corticosteroids, including diabetes, glaucoma, or cataracts. For pregnant women, Norheum is classified as Pregnancy Category C, meaning use is only permitted when the potential benefit outweighs the documented risk to the fetus. Caution should be exercised if the medicine is used while breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Norheum, which contains Nicotinamide Riboside (NR), may interact with certain classes of medicinal products, primarily due to its potential physiological effects.

Product Class	Interaction Mechanism	Clinical Relevance & Constraint
Antihypertensive Drugs (Medications for High Blood Pressure)	Norheum may have an additive effect on blood pressure lowering (hypotension). NR has been associated with promoting vasodilation, which may enhance the effects of existing antihypertensive therapy.	Requires close blood pressure monitoring when used concurrently to prevent blood pressure from dropping too low.
Antidiabetic Agents (Medications for Diabetes)	Norheum/NAD+ precursors may influence glucose metabolism and insulin sensitivity, potentially affecting the efficacy of blood sugar-lowering medicines such as insulin or metformin.	Blood glucose levels must be closely monitored, and medication doses may need adjustment by a healthcare provider.
Anticoagulants (Blood Thinners)	Norheum, as a form of Vitamin B3, may influence the metabolism of anticoagulants like warfarin, potentially altering the clotting time.	Patients on blood thinners may require more frequent testing, such as monitoring the International Normalized Ratio (INR), to ensure safe use.
Cancer Treatments (Chemotherapy)	Some cancer treatments work by reducing cellular NAD+ levels. Supplementation with Norheum could theoretically interfere with the intended mechanism of these therapies.	Avoid co-administration or use only under the strict guidance of an oncologist.

Due to its role in fundamental cellular processes, consultation with a healthcare professional is essential before combining Norheum with any prescription medication, particularly those affecting blood pressure, blood glucose, or blood clotting.

Mechanism of Action

The action of Norheum (Betamethasone Dipropionate) is defined by its role as a synthetic glucocorticoid, engaging fundamental regulatory systems to dampen local physiological activity. Its mechanism relies on two core, cascading domains: Genomic Receptor Activation and Anti-Inflammatory Cascade Blockade.

Genomic Receptor Activation and Transcription Control

This mechanism is initiated by the active ingredient binding to the Cytosolic Glucocorticoid Receptor (GR), forming a complex that translocates into the cell nucleus. The complex then modulates the cell’s genetic expression by transrepressing pro-inflammatory transcription factors like NF-kappaB and transactivating anti-inflammatory genes (e.g., Annexin A1). This genomic control is central to the mechanism, influencing the resultant immunomodulatory activity by altering the production rate of regulatory proteins.

Anti-Inflammatory Cascade Blockade and Vasoconstriction

The resulting protein changes, specifically the increase in Annexin A1, lead to the inhibition of the enzyme Phospholipase A2 (PLA2). By blocking PLA2, the release of arachidonic acid is halted, thereby interrupting the entire cascade that synthesizes primary inflammatory mediators like prostaglandins and leukotrienes. This core suppression of mediator production, combined with a concurrent localized vasoconstriction of dermal blood vessels, results in the physiological decrease in capillary permeability and cellular movement toward the application site.

Dosage and Administration Information

How to Use Norheum

The usage of Norheum (Betamethasone Dipropionate topical, 0.05%) is governed by specific administration rules that reflect its classification as a high-potency corticosteroid. This section outlines the procedural guidelines for its application.

Administration Protocol

Norheum is strictly for topical use, meaning it must only be applied to the affected areas of the skin. It is not approved for ophthalmic, oral, or intravaginal application. The medicine is supplied in various formulations, including a cream, ointment, lotion, or gel at a standard strength of 0.05%.

Dosing and Frequency

Standard application involves gently rubbing a thin film onto the skin. The usual frequency is once daily or twice daily. To minimize the risk of systemic absorption, the maximum quantity applied for adults should not exceed 50 grams per week.

Duration and Restrictions

Treatment with Norheum is intended for short-term use. Continuous therapy is generally limited, such as no more than two consecutive weeks for certain high-potency augmented formulations. Therapy must be discontinued immediately upon achieving control of the condition. The medicine should not be covered with occlusive dressings (like bandages or plastic wrap) unless specifically advised by a healthcare professional.

Special Procedural Guidance

Procedural constraints dictate that application must be avoided on sensitive areas, including the face, groin, or axillae (underarms). After application, users should wash their hands thoroughly, except when the hands are the area being treated. For certain formulations, use is not recommended in pediatric patients younger than 13 years of age, establishing a clear age-specific administration rule.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Core Research Focus

Initial research evaluated whether Norheum could provide an effect on the symptoms of severe plaque psoriasis (PsO) in adult patients. Further research examined whether Norheum could be associated with a change in pain and inflammation related to active psoriatic arthritis (PsA).

Plaque Psoriasis (PsO) Outcomes

Study A: Short-Term Outcomes in PsO

Study A investigated outcomes of Norheum compared to placebo at week 16. The study included 920 adult patients with moderate-to-severe plaque psoriasis.

The primary endpoint, a 75% reduction in the Psoriasis Area and Severity Index (PASI 75), was reached by 78% of patients in the treatment group, with the difference compared to the placebo group (5%) being statistically notable.

Study B: Long-Term Data and Maintenance

Study B was designed to explore the long-term changes over a two-year period following the initial 16-week phase. A maintained finding of symptom changes was noted over the two-year study period; the study reported findings of interest.

Psoriatic Arthritis (PsA) Outcomes

Study C: Evaluation of Joint Symptoms

Study C explored whether Norheum was associated with changes in symptoms of active psoriatic arthritis. The primary outcome measure was the ACR 20 response rate (a composite measure of disease improvement) at week 24.

The result reported was an ACR 20 response rate of 62% for patients receiving Norheum, versus 35% in the placebo group.

Study D: Radiographic Progression Evaluation

Study D investigated the radiographic progression of joint structural damage in patients with PsA over one year. The study measured change from baseline in the modified Total Sharp Score (mTSS).

The study examined whether combining Norheum with methotrexate was associated with changes in joint function and structural damage. The mean change in mTSS from baseline to week 52 was observed to be 0.1 for the combination group compared to 0.8 for the placebo group.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Norheum (FAQ)

Q: Can Norheum be used for eczema?

Official regulatory documents indicate that Norheum (Betamethasone Dipropionate) is used to relieve the inflammation and itching associated with various corticosteroid-responsive skin conditions. Official product information notes that Betamethasone Dipropionate is often used for skin conditions such as eczema (atopic dermatitis) and psoriasis.

Q: How should I dispose of Norheum?

To ensure safety and protect the environment, unused or expired Norheum must not be disposed of in household trash or poured down a sink or toilet. It is important to follow local regulations for drug disposal. Many communities offer drug take-back programs, which are a recommended method for safe medication disposal.

Q: How long should I use Norheum before stopping?

According to the official product information, treatment with Norheum is intended for short-term use. Labeling suggests that therapy should be discontinued immediately once the condition is under control. Continuous use of certain high-potency augmented formulations is typically limited, such as to no more than two consecutive weeks.

Q: Can I use Norheum if I am pregnant or breastfeeding?

Regulatory documents classify Norheum as Pregnancy Category C, meaning use is generally permitted only if the potential benefit justifies the potential risk to the fetus. If you are breastfeeding, caution is advised, and the medicine should never be applied to the nipple or the area surrounding it to prevent ingestion by the infant.

Q: What are the side effects of Norheum?

Like all medicines, Norheum can cause side effects. Common local adverse reactions listed in the drug label may include burning, itching, irritation, dryness, and skin thinning (atrophy) at the application site. There is a risk of more serious systemic effects, such as HPA axis suppression (a change in the body's hormone regulation), especially with extensive or long-term use.

Q: What should I do if I accidentally swallow Norheum?

Norheum is strictly for external use on the skin and is not safe to ingest. If accidental swallowing occurs, it is important to immediately seek emergency medical help or contact a Poison Control Center right away.

Q: Can I use Norheum with other skin care products?

Official patient counseling information discusses applying other products to the treatment area. Official guidance suggests avoiding application of other topical products, including cosmetics, moisturizers, or skin care products, to the same areas where Norheum is being applied, unless specifically advised otherwise by a healthcare professional.

How should Norheum be stored and disposed of?

How to Store and Dispose of Norheum?

The storage and disposal of Norheum (Betamethasone Dipropionate) must strictly adhere to regulatory requirements to maintain product stability and ensure safety.

Storage Conditions

The product must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). It is a mandatory requirement to keep from freezing as this can compromise the formulation. The medicine must also be stored in its tightly closed, original container and be protected from light and excessive heat.

Stability and Safety

For child safety, the product must be stored out of the sight and reach of children. Some formulations may have a limited in-use stability period of approximately six months after first opening the tube, provided it is stored correctly.

Disposal Instructions

Unused or expired Norheum must be disposed of in accordance with local regulations and must not be disposed of via household waste or wastewater. Patients should utilize community drug take-back programs if available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Taiwan

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z